Detection, and treatment of hypertension and prevention of hypertension-associated target organ damage Circulatory System
Conditions
Interventions
Quantitative data will be collected by trained research assistants. We will screen 10,000 people in the 7 coastal communities in the Greater Accra Region to identify 3,000 people with hypertension. Th
Sponsors
Deutsche Gesellschaft für Internationale Zusammenarbeit
Bayer (Germany)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Current inclusion criteria as of 20/05/2024: 1. Resident in the Greater Accra Region of Ghana 2. Resident in the selected urban coastal communities 3. Aged 18 years or older as of last birthday 4. Have no intention of relocating outside of the study communities prior to enrolment and during the study period 5. Have a three-time blood pressure recording with a mean of =140/90mmhg at the time of recruitment 6. Newly diagnosed hypertensive; and 7. Willing to participate and has the ability to give consent. _____ Previous inclusion criteria: Adults 18 years and above in coastal communities in the Greater Accra Region of Ghana
Exclusion criteria
Exclusion criteria: 1. Not a resident of the Greater Accra region and the selected coastal communities 2. Residents who intend to travel or re-locate before or during the study period 3. Known hypertensive participants who are already on medication 4. Known end-organ dysfunction on treatment 5. Not willing to participate in the study or do not give consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Current primary outcome measure as of 20/05/2024: Measured at baseline, 6, and 12 months: 1. Blood pressure measured using a sphygmomanometer 2. Hypertension mediated target organ damage (HMTOD): 2.1. ECG and ECHO for heart damage 2.2 Creatinine, proteinuria _____ Previous primary outcome measure: Measured at baseline, 6, and 12 months: 1. Blood pressure measured using a sphygmomanometer 2. Hypertension mediated target organ damage (HMTOD): 2.1. ECG and ECHO for heart damage 2.2. Proteinuria and Creatinine for kidney damage | — |
Secondary
| Measure | Time frame |
|---|---|
| Current secondary outcome measures as of 20/05/2024: 1. Baseline prevalence of hypertension 2. The proportion of hypertensive patients linked to care in an urban coastal community in Accra measured using patient records at the end of the study 3. Medication adherence rate among hypertensive patients linked to care measured using Hill-Bone HBP Compliance to High Blood Pressure Therapy Scale (HB-HBP) at baseline, 6, and 12 months 4. The perception and lived experiences of community members on hypertension and its management measured using in-depth interviews and focus group discussions at baseline _____ Previous secondary outcome measures: 1. Proportion of hypertensive patients linked to care in an urban coastal community in Accra measured using patient records at the end of the study 2. Medication adherence rate among hypertensive patients linked to care measured using Hill-Bone HBP Compliance to High Blood Pressure Therapy Scale (HB-HBP) at baseline, 6, and 12 months 3. The perception and lived experiences of community members on hypertension and its management measured using in-depth interviews and focus group discussions at baseline | — |
Countries
Ghana
Contacts
Public ContactVincent Boima
Outcome results
None listed